Submit adequate justification: CDSCO Panel tells Synokem pharma about Phase III CT of Naftifine Cream

Published On 2022-10-26 06:15 GMT   |   Update On 2022-10-26 06:15 GMT
Advertisement

New Delhi: Regarding the ongoing Phase III Clinical trial with the drug Naftifine HCI Cream 2%w/w, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has opined drug major Synokem Pharma to submit the adequate justification/rationale for the proposed un-blinding of randomization and interim analysis of data before the committee.

This came after the firm presented their proposal for the un-blinding of randomization and interim analysis of data of all patients after completing the visit 4 (i.e. Day 42±3 days/week 6) of the ongoing Phase III Clinical trial with the drug Naftifine HCI Cream 2%w/w.

A 'blind' study is a clinical trial in which the subject or the Investigator (or both) are unaware of which trial product/drug the subject is taking. When only one is blinded to the data this is a 'single blind' study. When both do not know the treatment, the study is 'double-blind'. Studies in which the participant takes part in three arms, such as placebo, active drug and comparative drug remain as double blind.

Unblinding is the process by which the allocation code is broken so that the Clinical trial investigator (CI) and/or trial statistician becomes aware of the intervention.

Naftifine is a synthetic, broad spectrum, antifungal agent and allylamine derivative for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans and Epidermophyton floccosum.

Although the exact mechanism of action against fungi is not known, naftifine appears to interfere with sterol biosynthesis by inhibiting the enzyme squalene 2,3-epoxidase. This inhibition of enzyme activity results in decreased amounts of sterols, especially ergosterol, and a corresponding accumulation of squalene in the cells.

At the recent SEC meeting for Dermatology and Allergy held on October 13th,2022 the expert panel extensively evaluated the proposal presented by Synokem Pharma for the un-blinding of randomization and interim analysis of data of all patients after completing the visit 4 (i.e. Day 42±3 days/week 6) of the ongoing Phase III Clinical trial with the drug Naftifine HCI Cream 2%w/w
After detailed deliberation, the committee opined that the firm should submit the adequate justification/rationale for the proposed un-blinding of randomization and interim analysis of data before the committee for further consideration of the matter.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News